Skip to main content
Erschienen in: Pediatric Radiology 11/2019

01.10.2019 | Pediatric oncologic imaging

Surveillance imaging in pediatric lymphoma

verfasst von: Stephan D. Voss, Mitchell S. Cairo

Erschienen in: Pediatric Radiology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Current therapies used in treating children with Hodgkin lymphoma and many histological subtypes of non-Hodgkin lymphoma have resulted in overall survival rates exceeding 90% in many instances. With increasing concerns related to the cost of radiologic imaging, exposure to ionizing radiation, and potential false-positive results, the role of routine off-therapy surveillance imaging has been called into question. Although radiologic imaging plays an important role in diagnosing and assessing treatment response, in these children — the majority of whom have an excellent outcome following completion of therapy — there is an opportunity to dramatically reduce the number of off-therapy imaging evaluations. This review summarizes several recent studies in both Hodgkin and non-Hodgkin lymphoma providing evidence to support these efforts. In addition, we propose a surveillance imaging strategy that uses a novel risk-adapted and response-based approach to determine which children would most benefit from off-therapy imaging surveillance.
Literatur
1.
Zurück zum Zitat Cairo MS, Beishuizen A (2019) Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives. Br J Haematol 185:1021–1042CrossRef Cairo MS, Beishuizen A (2019) Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives. Br J Haematol 185:1021–1042CrossRef
2.
Zurück zum Zitat Patte C, Auperin A, Gerrard M et al (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109:2773–2780CrossRef Patte C, Auperin A, Gerrard M et al (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109:2773–2780CrossRef
3.
Zurück zum Zitat Cairo MS, Pinkerton R (2016) Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. Br J Haematol 173:507–530CrossRef Cairo MS, Pinkerton R (2016) Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. Br J Haematol 173:507–530CrossRef
4.
Zurück zum Zitat Cairo MS, Sposto R, Gerrard M et al (2012) Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol 30:387–393CrossRef Cairo MS, Sposto R, Gerrard M et al (2012) Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol 30:387–393CrossRef
5.
Zurück zum Zitat Giulino-Roth L, Keller FG, Hodgson DC et al (2015) Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents. Br J Haematol 169:647–660CrossRef Giulino-Roth L, Keller FG, Hodgson DC et al (2015) Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents. Br J Haematol 169:647–660CrossRef
6.
Zurück zum Zitat Goldman S, Smith L, Anderson JR et al (2013) Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia 27:1174–1177 Goldman S, Smith L, Anderson JR et al (2013) Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia 27:1174–1177
7.
Zurück zum Zitat Goldman S, Smith L, Galardy P et al (2014) Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group report. Br J Haematol 167:394–401 Goldman S, Smith L, Galardy P et al (2014) Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group report. Br J Haematol 167:394–401
8.
Zurück zum Zitat Hochberg J, Cairo MS (2018) Lymphoma in adolescents and young adults: current perspectives. Cancer J 24:285–300CrossRef Hochberg J, Cairo MS (2018) Lymphoma in adolescents and young adults: current perspectives. Cancer J 24:285–300CrossRef
9.
Zurück zum Zitat Kelly KM, Hodgson D, Appel B et al (2013) Children's oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 60:972–978CrossRef Kelly KM, Hodgson D, Appel B et al (2013) Children's oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 60:972–978CrossRef
10.
Zurück zum Zitat Smith MA, Altekruse SF, Adamson PC et al (2014) Declining childhood and adolescent cancer mortality. Cancer 120:2497–2506CrossRef Smith MA, Altekruse SF, Adamson PC et al (2014) Declining childhood and adolescent cancer mortality. Cancer 120:2497–2506CrossRef
11.
Zurück zum Zitat Kaste SC (2011) Oncological imaging: tumor surveillance in children. Pediatr Radiol 41:505–508CrossRef Kaste SC (2011) Oncological imaging: tumor surveillance in children. Pediatr Radiol 41:505–508CrossRef
12.
Zurück zum Zitat Voss SD, Reaman GH, Kaste SC et al (2009) The ALARA concept in pediatric oncology. Pediatr Radiol 39:1142–1146CrossRef Voss SD, Reaman GH, Kaste SC et al (2009) The ALARA concept in pediatric oncology. Pediatr Radiol 39:1142–1146CrossRef
13.
Zurück zum Zitat McHugh K, Roebuck DJ (2014) Pediatric oncology surveillance imaging: two recommendations. Abandon CT scanning, and randomize to imaging or solely clinical follow-up. Pediatr Blood Cancer 61:3–6CrossRef McHugh K, Roebuck DJ (2014) Pediatric oncology surveillance imaging: two recommendations. Abandon CT scanning, and randomize to imaging or solely clinical follow-up. Pediatr Blood Cancer 61:3–6CrossRef
14.
Zurück zum Zitat Keller FG, Castellino SM, Chen L et al (2018) Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children's Oncology Group. Cancer 124:3210–3219 Keller FG, Castellino SM, Chen L et al (2018) Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children's Oncology Group. Cancer 124:3210–3219
15.
Zurück zum Zitat Rathore N, Eissa HM, Margolin JF et al (2012) Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol 29:415–423CrossRef Rathore N, Eissa HM, Margolin JF et al (2012) Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol 29:415–423CrossRef
16.
Zurück zum Zitat Voss SD (2013) Surveillance imaging in pediatric Hodgkin lymphoma. Curr Hematol Malig Rep 8:218–225CrossRef Voss SD (2013) Surveillance imaging in pediatric Hodgkin lymphoma. Curr Hematol Malig Rep 8:218–225CrossRef
18.
Zurück zum Zitat Howell L, Mensah A, Brennan B et al (2005) Detection of recurrence in childhood solid tumors. Cancer 103:1274–1279CrossRef Howell L, Mensah A, Brennan B et al (2005) Detection of recurrence in childhood solid tumors. Cancer 103:1274–1279CrossRef
19.
Zurück zum Zitat Voss SD, Chen L, Constine LS et al (2012) Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol 30:2635–2640 Voss SD, Chen L, Constine LS et al (2012) Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol 30:2635–2640
20.
Zurück zum Zitat Friedmann AM, Wolfson JA, Hudson MM et al (2013) Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy. Pediatr Blood Cancer 60:1458–1463CrossRef Friedmann AM, Wolfson JA, Hudson MM et al (2013) Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy. Pediatr Blood Cancer 60:1458–1463CrossRef
21.
Zurück zum Zitat Satwani P, Jin Z, Martin PL et al (2015) Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia 29:448–455CrossRef Satwani P, Jin Z, Martin PL et al (2015) Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia 29:448–455CrossRef
22.
Zurück zum Zitat Kapke JT, Epperla N, Shah N et al (2017) Effect of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma after autologous hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 17:408–414 Kapke JT, Epperla N, Shah N et al (2017) Effect of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma after autologous hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 17:408–414
23.
Zurück zum Zitat Sandlund JT (2015) Non-Hodgkin lymphoma in children. Curr Hematol Malig Rep 10:237–243CrossRef Sandlund JT (2015) Non-Hodgkin lymphoma in children. Curr Hematol Malig Rep 10:237–243CrossRef
24.
Zurück zum Zitat Cairo M, Auperin A, Perkins SL et al (2018) Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. Br J Haematol 182:859–869CrossRef Cairo M, Auperin A, Perkins SL et al (2018) Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. Br J Haematol 182:859–869CrossRef
25.
Zurück zum Zitat Rosolen A, Perkins SL, Pinkerton CR et al (2015) Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol 33:2112–2118CrossRef Rosolen A, Perkins SL, Pinkerton CR et al (2015) Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol 33:2112–2118CrossRef
26.
Zurück zum Zitat Sandlund JT, Guillerman RP, Perkins SL et al (2015) International pediatric non-Hodgkin lymphoma response criteria. J Clin Oncol 33:2106–2111CrossRef Sandlund JT, Guillerman RP, Perkins SL et al (2015) International pediatric non-Hodgkin lymphoma response criteria. J Clin Oncol 33:2106–2111CrossRef
27.
Zurück zum Zitat Eissa HM, Allen CE, Kamdar K et al (2014) Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol 31:253–257CrossRef Eissa HM, Allen CE, Kamdar K et al (2014) Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol 31:253–257CrossRef
28.
Zurück zum Zitat El-Galaly TC, Jakobsen LH, Hutchings M et al (2015) Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol 33:3993–3998CrossRef El-Galaly TC, Jakobsen LH, Hutchings M et al (2015) Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol 33:3993–3998CrossRef
29.
Zurück zum Zitat Ahmed BA, Connolly BL, Shroff P et al (2010) Cumulative effective doses from radiologic procedures for pediatric oncology patients. Pediatrics 126:e851–e858CrossRef Ahmed BA, Connolly BL, Shroff P et al (2010) Cumulative effective doses from radiologic procedures for pediatric oncology patients. Pediatrics 126:e851–e858CrossRef
30.
Zurück zum Zitat Robbins E (2008) Radiation risks from imaging studies in children with cancer. Pediatr Blood Cancer 51:453–457CrossRef Robbins E (2008) Radiation risks from imaging studies in children with cancer. Pediatr Blood Cancer 51:453–457CrossRef
31.
Zurück zum Zitat Chong AL, Grant RM, Ahmed BA et al (2010) Imaging in pediatric patients: time to think again about surveillance. Pediatr Blood Cancer 55:407–413CrossRef Chong AL, Grant RM, Ahmed BA et al (2010) Imaging in pediatric patients: time to think again about surveillance. Pediatr Blood Cancer 55:407–413CrossRef
32.
Zurück zum Zitat Goldman S, Barth M, Hochberg J et al (2018) Reduced burden of oncologic therapy in children, adolescents and young adults with good risk (GR) CD20+ mature B-cell lymphoma. Br J Haematol 182:10CrossRef Goldman S, Barth M, Hochberg J et al (2018) Reduced burden of oncologic therapy in children, adolescents and young adults with good risk (GR) CD20+ mature B-cell lymphoma. Br J Haematol 182:10CrossRef
33.
Zurück zum Zitat Hochberg JC, Klejmont L, Harrison L et al (2018) Brentuximab vedotin and rituximab with reduced toxicity chemotherapy in children, adolescents and young adults with newly diagnosed Hodgkin lymphoma. Br J Haematol 182:91 Hochberg JC, Klejmont L, Harrison L et al (2018) Brentuximab vedotin and rituximab with reduced toxicity chemotherapy in children, adolescents and young adults with newly diagnosed Hodgkin lymphoma. Br J Haematol 182:91
34.
Zurück zum Zitat Bhakta N, Liu Q, Ness KK et al (2017) The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet 390:2569–2582 Bhakta N, Liu Q, Ness KK et al (2017) The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet 390:2569–2582
35.
Zurück zum Zitat Bhatia S, Robison LL, Oberlin O et al (1996) Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745–751CrossRef Bhatia S, Robison LL, Oberlin O et al (1996) Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745–751CrossRef
36.
Zurück zum Zitat Bhatia S, Yasui Y, Robison LL et al (2003) High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 21:4386–4394 Bhatia S, Yasui Y, Robison LL et al (2003) High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 21:4386–4394
37.
Zurück zum Zitat Bluhm EC, Ronckers C, Hayashi RJ et al (2008) Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 111:4014–4021 Bluhm EC, Ronckers C, Hayashi RJ et al (2008) Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 111:4014–4021
38.
Zurück zum Zitat Ehrhardt MJ, Sandlund JT, Zhang N et al (2017) Late outcomes of adult survivors of childhood non-Hodgkin lymphoma: a report from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 64 Ehrhardt MJ, Sandlund JT, Zhang N et al (2017) Late outcomes of adult survivors of childhood non-Hodgkin lymphoma: a report from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 64
39.
Zurück zum Zitat Holmqvist AS, Chen Y, Berano Teh J et al (2019) Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma — identification of high-risk populations to guide surveillance: a report from the Late Effects Study Group. Cancer 125:1373–1383 Holmqvist AS, Chen Y, Berano Teh J et al (2019) Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma — identification of high-risk populations to guide surveillance: a report from the Late Effects Study Group. Cancer 125:1373–1383
40.
Zurück zum Zitat Ehrhardt MJ, Chen Y, Sandlund JT et al (2019) Late health outcomes following contemporary Lymphome Malin de Burkitt therapy for mature B-cell non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol 8:JCO1900525 Ehrhardt MJ, Chen Y, Sandlund JT et al (2019) Late health outcomes following contemporary Lymphome Malin de Burkitt therapy for mature B-cell non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol 8:JCO1900525
41.
Zurück zum Zitat Dorffel W, Riepenhausen M, Luders H et al (2016) Late effects following treatment of Hodgkin lymphoma during childhood and adolescence. Results of the Hodgkin lymphoma late effects research project. Klin Padiatr 228:286–293CrossRef Dorffel W, Riepenhausen M, Luders H et al (2016) Late effects following treatment of Hodgkin lymphoma during childhood and adolescence. Results of the Hodgkin lymphoma late effects research project. Klin Padiatr 228:286–293CrossRef
42.
Zurück zum Zitat Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068CrossRef Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068CrossRef
Metadaten
Titel
Surveillance imaging in pediatric lymphoma
verfasst von
Stephan D. Voss
Mitchell S. Cairo
Publikationsdatum
01.10.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Radiology / Ausgabe 11/2019
Print ISSN: 0301-0449
Elektronische ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-019-04511-4

Weitere Artikel der Ausgabe 11/2019

Pediatric Radiology 11/2019 Zur Ausgabe

Pediatric oncologic imaging

Imaging of DICER1 syndrome

Pediatric Oncologic Imaging

Imaging of pediatric cutaneous melanoma

Pediatric oncologic imaging

Imaging of Wilms tumor: an update

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.